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Abstract
Background—The ability of chronic valproate (VPA) to reduce arachidonic acid (AA) turnover
in brain phospholipids of unanesthetized rats has been ascribed to its inhibition of acyl-CoA
synthetase (Acsl)-mediated activation of AA to AA-CoA. Our aim was to identify a rat Acsl
isoenzyme that could be inhibited by VPA in vitro.
Methods—Rat Acsl3-, Acsl6v1- and Acsl6v2-, and Acsl4-flag proteins were expressed in E.
coli, and the ability of VPA to inhibit their activation of long-chain fatty acids to acyl-CoA was
estimated using Michaelis-Menten kinetics.
Results—VPA uncompetitively inhibited Acsl4-mediated conversion of AA and of
docosahexaenoic (DHA) but not of palmitic acid to acyl-CoA, but did not affect AA conversion by
Acsl3, Acsl6v1 or Acsl6v2. Acsl4-mediated conversion of AA to AA-CoA showed substrate
inhibition and had a 10-times higher catalytic efficiency than did conversion of DHA to DHA-
CoA. Butyrate, octanoate, or lithium did not inhibit AA activation by Acsl4.
Conclusions—VPA’s ability to inhibit Acsl4 activation of AA and of DHA to their respective
acyl-CoAs, related to the higher catalytic efficiency of AA than DHA conversion, may account for
VPA’s selective reduction of AA turnover in rat brain phospholipids, and contribute to VPA’s
efficacy against bipolar disorder.
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Valproate (VPA), a branched-chain achiral eight-carbon isooctanoic acid, is approved by the
FDA for treating bipolar disorder (BD), but it is teratogenic and its efficacy against BD is
incomplete [1]. Understanding the mechanism of action of VPA and its brain target as a
basis of its efficacy against BD may help to design more effective, less toxic drugs [2].
One suggested mechanism of action of VPA against BD, as well as of carbamazepine and
lithium, is based on evidence that each of these mood stabilizers, when given chronically to
rats to produce therapeutically relevant plasma concentrations, downregulated arachidonic
acid (AA, 20:4n-6) but not docosahexaenoic acid (DHA, 22:6n-3) or (in the case of lithium)
palmitate (16:0) turnover in brain phospholipids. This common effect agrees with the fact
that the postmortem BD brain demonstrates upregulated markers of AA metabolism,
associated with neuroinflammation, excitotoxicity and apoptosis [2–5]. Similar associations
between these neuropathological processes and upregulated brain AA metabolic markers
have been identified in animal models [6–8].
Reduced brain AA turnover in unanesthetized rats given lithium or carbamazepine correlates
with downregulation of mRNA, protein and activity of Ca2+-dependent cytosolic
phospholipase A2 (cPLA2) type IV, which selectively hydrolyzes AA (compared with DHA)
from membrane phospholipid in vitro [2,9,10], as well with reduced activity of
cyclooxygenase (COX)-2; COX-2 is functionally coupled to cPLA2 and converts AA to
prostaglandin E2 and other proinflammatory eicosanoids [11–14]. Chronic VPA did not
downregulate rat brain cPLA2, but did reduce net brain COX activity and protein levels of
both COX-1 and COX-2 [15]. VPA also reduced the rate of conversion of AA to AA-CoA,
but not of DHA to DHA-CoA, in a rat brain microsomal fraction having acyl-CoA
synthetase (Acsl, E.C.6.2.1.3) activity [16]. VPA itself is not a substrate for rat brain
microsomal Acsl [16], and neither valproyl-CoA nor esterified VPA was found in the brain
of rats following chronic administration of the drug [17]. Inhibition of conversion to acyl-
CoA may underlie VPA’s selective reduction of AA turnover in rat brain phospholipids in
vivo [18].
Twenty-six human ACSL genes have been identified within five subfamilies, based on chain
length of the preferred acyl groups [19]. Five human long-chain Acsl proteins have been
characterized, represented by multiple splice variants, yielding 15 isoenzymes that
preferably acylate fatty acids of 12–22 carbon length. In rats, each of four ACSL genes
(ACSL1, ACSL3, ACSL4, and ACSL5) is represented by only one variant, whereas ACSL6
is represented by two splice variants (ACSL6v1 and ACSL6v2) [20]. Each isozyme has a
distinct tissue distribution, subcellular location and fatty acid preferences. Acsl3, Acsl6v1,
and Acsl6v2 are the predominant isoforms in rat brain, whereas Acsl1 and Acsl5 are
expressed mainly in liver and adipose tissue [21–23]. Acsl3 and Acsl 6 act on AA
preferentially among C14–C22 unsaturated fatty acids, compared to Acsl1 and Acsl5 [23].
Acsl4 has a marked preference for AA [23], and is expressed in neurons but not glial cells in
the human cerebellum and hippocampus, where it may be required for dendritic spine
formation [24,25]. No mammalian Acsl enzyme has been crystallized or has a published
structure.
In view of the finding that conversion of AA compared with DHA to its respective acyl-CoA
by the rat brain microsomal fraction was inhibited by VPA [16], we thought it worthwhile to
try to identify a specific rat Acsl whose conversion of AA to AA-CoA could be inhibited by
VPA. To do this, we quantified inhibition by VPA of AA, DHA and palmitic acid
conversion to their respective acyl-CoAs with recombinant rat Acsl3, Acsl4 and Acsl6
isoenzymes. We did not study Acsl1 or Acsl5 because of their reported low selectivity for
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[1-14C]AA (50 mCi/mmol), [1-14C]DHA (56 mCi/mmol) and [14C]palmitic acid (56 mCi/
mmol) were purchased from Moravek Biochemicals (Brea, CA). Fatty acids, sodium VPA,
sodium octanoate, sodium butyrate, triacsin C, LiCl, coenzyme A, ATP, anti-Flag M2
monoclonal mouse antibody, and goat anti-mouse IgG-peroxidase conjugate were purchased
from Sigma (St. Louis, MO).
Preparation of bacterial lysate
Recombinant plasmids for rat brain ACSL3, ACSL6v1 and ACSL6v2, and for rat liver
ACSL4-Flag, were expressed in E. Coli strain BL21-codonPlus (DE3)-RIL [20,26,27]. As a
negative control, the same strain, transformed with the empty vector, was used under
identical conditions. Recombinant Acsl-Flag proteins were induced with 1 mM isopropyl-β-
D-1-thiogalactopyranoside (IPTG) at A600 = 1.0. E. Coli was grown in Terrific Broth
medium supplemented with carbenicillin (final concentration 50 μg/ml) at 37 °C and shaken
at 206 rpm. After a 6-h induction, cells were harvested by centrifugation at 4000 g for 20
min in a Sorval SA-600 rotor at 4°C. The cell pellet was resuspended in a buffer containing
10 mM HEPES (pH 7.8) and 0.5 mM EDTA, and sonicated on ice with six 10-s bursts each
followed by a 10-s rest, using a cell disruptor sonicator (Heat Systems Ultrasonics,
Farmingdale, NY) at setting 4. Lysate aliquots were stored at −80°C for enzyme assay.
Protein concentrations were determined by the Bradford method [28].
Relative Protein Determination and Western Blot Analysis
Cell lysates (1 μg) of each isozyme were separated by electrophoresis on a 10–20% SDS-
PAGE, transferred to a polyvinylidene fluoride membrane (Bio-Rad), and incubated with
anti-Flag M2 monoclonal antibody. For chemiluminescence detection, immunoreactive
bands were visualized by incubating the membranes with horseradish peroxidase-conjugated
antibodies followed by PicoWest reagents (Thermo Fisher Scientific, Rockford, IL). NIH
ImageJ software was used for densitometry analysis. The amount of final cell-lysate per tube
(1 μg) was normalized to the band intensity of each isozyme, yielding the relative isozyme
concentration.
Acsl Activity Assay
Acsl activity was measured using 1–3 μg protein. The assay medium contained 175 mM
Tris-HCl pH 7.4, 8 mM MgCl2, 5 mM dithiothreitol, 10 mM ATP, 0.25 mM CoA, 0.01 mM
EDTA, and 5 μM [14C]fatty acid in 0.5 mM Triton X-100, and increasing concentrations of
the unlabeled fatty acids in a total volume of 200 μl. Sodium VPA (0, 10, 30, 60 or 90 mM)
or lithium chloride (0, 10 or 30 mM) was added directly to the reaction mixture during
inhibition assays. Triacsin C, an inhibitor of Acsl1, Acsl3 and Acsl4 [27], was added
directly to the reaction mixture at 10 μM as a positive control. As additional controls,
sodium octanoate (a constitutional isomer of VPA) or sodium butyrate (a short-chain VPA
analogue) was added to the reaction mixture at 60 mM. Assays were performed at 37°C for
5 min with shaking. The reaction was started by adding 15 μl bacterial lysate to the reaction
mixture, and was terminated by adding 1 ml Dole’s Reagent (isopropanol:heptane:1 M
H2SO4, 80:20:2, by vol). In a preliminary experiment, the pH of reaction mixtures spiked
with VPA and sodium octanoate at concentrations of 60 and 90 mM was measured using a
pH meter. The pH (7.4) remained constant at these drug concentrations. Unesterified fatty
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acids were removed with two 2-ml heptane washes and acyl-CoA radioactivity was
measured by liquid scintillation counting. As a negative control, Acsl enzyme activity of the
E. Coli cell lysate lacking a gene coding for ACSL-Flag was measured with AA as substrate
as described above. The results were corrected for blanks (samples without cell lysates
added and samples analyzed in the absence of fatty acids).
Analysis and Statistics
For each Acsl, initial reaction velocity V was plotted against substrate concentrations at each
VPA concentration Io and the plots were fitted by least squares to a hyperbolic Michaelis-
Menten model using GraphPad Prism version 5.00 (GraphPad Software, San Diego, CA).
Km (μM) and Vmax (nmol/min/mg protein) were calculated by the following equation, in
which V is reaction velocity (nmol acyl-CoA formed/min/mg enzyme protein, e.g. nmol/
min/mg protein) at a given fatty acid substrate concentration, S (μM),
(1)
Catalytic efficiency, which reflects turnover of the enzyme, was calculated from the ratio of
Vmax to Km, normalized to the relative enzyme concentration (ET, mg/l) [29],
(2)
The model in which substrate inhibits reaction velocity can be described as [30],
(3)
A model that involves both substrate inhibition and uncompetitive inhibition by inhibitor Io
can be represented as,
(4)
where Ki is the enzyme inhibition constant.
Data were plotted as a function of inhibitor concentration Io [e.g., VPA, LiCl, sodium
octanoate or butyrate, see Results], and the enzyme inhibition constant (Ki) was derived
from the ascending part of the plot. Lineweaver-Burk plots of 1/V vs. 1/S in the presence of
different inhibitor concentrations also were plotted.
Selection of the model
To determine which inhibition model best described the data, we utilized the Akaike
Information Criterion (AIC) [31]
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where k = number of parameters and L = maximized value of the likelihood function of the
model. For small sample sizes, the AIC is corrected and is given by AICc [32]
(6)
Where ss is the sum of squares from the fit, N is the number of experimental observations
and K is the number of parameters in the models. As the goodness of fit of a model to the
measured data improves, the value of AIC declines. Therefore, AICc is a formal method to
evaluate model quality and simplicity.
The probability that the model is correct can be determined by the following equation, where
Δ is the difference between AICc scores [32]
(7)
For this current study with AA as a substrate, the lowest AICc was found for the
“uncompetitive inhibition” model. The difference between AICc values for the
uncompetitive and noncompetitive enzyme inhibition models was 3.266. The probability
that the uncompetitive model was correct was 84%, compared to 16% for the
noncompetitive model.
Using DHA as a substrate, the uncompetitive inhibition model also gave the lowest AICc.
The difference between AICc was 3.178 for uncompetitive and noncompetitive enzyme
inhibition. For inhibition of DHA, the probability that the uncompetitive inhibition model
was correct was 83% vs. 17% for the noncompetitive model.
Data are presented as means ± S.D. Means were compared using unpaired, two-tailed
Student t-tests. Linear regression analysis and other calculations were made using GraphPad
Prism version 5.0 (GraphPad Software, La Jolla, CA).
Results
Enzyme expression
An optimal induction of recombinant rat Acsl isoenzyme synthesis was achieved following a
6-h incubation with 1 mM IPTG (Figure 1). The 74-kDa band of recombinant Acsl was
detected by Western blotting. No signal or Acsl activity (AA as a substrate, data not shown)
was observed in the E. Coli strain lacking a gene encoding a recombinant Acsl.
Acsl3, Acsl6v1 and Acsl6v2 kinetics
Reaction kinetics involving conversion of AA to AA-CoA by Acsl3, Acsl6v1 and Acsl6v2
in the absence of VPA followed a simple Michaelis-Menten model, as illustrated in Figure
2(a, b, c). Fitting Eq. 1 to these data gave value of Km ranging from 23 to 48 μM for the
three enzymes, and Vmax ranging from 0.5 to 8 nmol/min/mg of protein (Table 1). Acsl3 and
Acsl6v1 had similar catalytic efficiencies (maximum number of molecules of substrate that
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an enzyme can convert to product per catalytic site per unit time, Eq. 2) for AA activation,
1.3 – 3 × 10−5 min−1, while the catalytic efficiency of Acsl6v2 was much less, 4 × 10−6
min−1 (Table 1). Also illustrated in Figure 2(a, b, c), VPA up to a concentration of 60 mM
did not inhibit activation of AA to AA-CoA by Acsl3, Acsl6v1 or Acsl6v2. Triacsin C (10
μM) inhibited activation by Acsl3 by 90% (data not shown), as reported [20].
Acsl4 kinetics
With regard to Acsl4, Figure 3a illustrates that as the substrate AA concentration was
elevated at different VPA concentrations in the medium, the initial velocity V for AA-CoA
formation first increased, and then decreased at an AA concentration higher than about 35
μM. This biphasic pattern is consistent with substrate inhibition at high substrate
concentrations (Eq. 3) [30]. In contrast, in the absence of VPA and with palmitic acid or
DHA as the substrate, the reaction with Acsl4 followed simple Michaelis-Menten kinetics
and the curves were asymptotic (Figures 4 and 5a).
Figure 3b presents Lineweaver-Burk plots (1/V vs. 1/[AA]) for Acsl4, at each of four VPA
concentrations Io (0, 30, 60 and 90 mM), and Figure 5b presents plots of 1/V vs. 1/[DHA] at
different VPA concentrations. To calculate the plots in Figure 3b, we only considered AA
concentrations in the rising phase of the V vs. [AA] curves, from 0 to 35 μM AA, since at
higher AA concentrations the enzyme showed substrate inhibition (Figure 3a)., We
considered the entire range of DHA concentrations because of the absence of apparent
substrate inhibition in Figure 5a. The Lineweaver-Burk plots in both Figures 3b and 5b have
parallel slopes at different VPA concentrations, characteristic of uncompetitive inhibition by
VPA (Eq. 4) [30]. Uncompetitive inhibitors bind to the enzyme-substrate complex but not to
the free enzyme, resulting in a conformational change in the enzyme. An uncompetitive
inhibitor does not compete with the substrate at the same binding site, so that inhibition
cannot be overcome by increasing the substrate concentration. Both Km and Vmax are
reduced by uncompetitive inhibition.
Table 2 summarizes Michaelis-Menten parameters for Acsl4 with AA, DHA and palmitic
acid as substrates, as well as catalytic efficiencies, derived by curve-fitting data in Figure 3b.
In the absence of VPA, Km for AA was 3–5 fold less than for DHA or palmitic acid. Vmax
for AA was somewhat higher than for DHA, but Vmax for both fatty acids was about 4-fold
higher than Vmax for palmitic acid. Importantly, the catalytic efficiency of Acsl4 with AA as
substrate was about 11 times higher than with DHA or palmitic acid as substrate. Acsl4
exhibited 300–2200 higher catalytic efficiency with AA as substrate than did Acsl3, Acsl6v1
or Acsl6v2 (Table 1).
VPA inhibits Acsl4-mediated acylation of AA and DHA
VPA inhibited activation by Acsl4 of AA and of DHA to their respective acyl-CoA products
(Table 2 and Figures 3 and 5), but had no inhibitory effect with palmitic acid as substrate
(Figure 4). Inhibition with AA and DHA as substrates is consistent with an uncompetitive
mechanism (Figures 3b and 5b). The Ki for inhibition of AA and DHA acylation equaled 25
and 36 mM, respectively. Acsl4 also was 85% inhibited by 10 μM triacsin C (data not
shown), as reported [20,27].
As an additional control for VPA’s specificity, we tested for inhibition of AA conversion to
AA-CoA by Acsl4 with sodium octanoate and butyrate. At a concentration of 60 mM,
neither agent changed the kinetics of AA acylation by Acsl4 (Figure 6). To test whether
Acsl4 might be a target of another mood stabilizer, we determined Acsl4 kinetics in the
presence of increasing LiCl concentrations (0, 10 and 30 mM). Lithium at each
concentration tested had no effect on Acsl4 kzinetics (Figure 3a).
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We characterized in vitro kinetics of each of four rat recombinant rat Acsl isoenzymes
expressed in E. Coli, with regard to their conversion of AA, DHA or palmitic acid to acyl-
CoA products, and examined effects of VPA and other potential inhibitors. In the absence of
VPA, rat liver Acsl4 had a much lower Km (higher affinity) for acylation of AA to AA-CoA
than did rat brain Acsl3, Acsl6v1 or Acsl6v2, consistent with previous reports on rat as well
as human Acsl enzymes [20,23,33]. Acsl4 had a 3 to 5-fold lower Km with AA than with
DHA or palmitic acid as its substrate, also consistent with its reported fatty acid selectivity
[23]. The Vmax of Acsl4 was about equal with either AA or DHA as substrate, but in both
cases was much higher than the Vmax with palmitic acid as substrate. The catalytic
efficiency of Acsl4 was more than 10-fold higher with AA than with DHA as substrate, and
30-fold higher than with palmitate as substrate.
VPA inhibited acylation of AA and DHA by Acsl4 but not by Acsl3, Acsl6v1 or Acsl6v2.
However, neither VPA’s constitutional isomer, octanoate, nor its short-chain analog,
butyrate, inhibited AA acylation, nor did lithium at concentrations up to 30 mM (therapeutic
plasma range is 0.6–1.2 mM [1]). Thus, inhibition is specific and does not characterize all
mood stabilizers.
Simple Michaelis-Menten kinetics held for AA acylation by Acsl3, Acsl6v1 and Acsl6v2,
and for palmitate and DHA acylation by Acsl4 but not for AA acylation by Acsl4. The
biphasic relation between velocity of AA acylation and AA concentration with Acsl4, in the
absence of VPA, indicates substrate inhibition at higher AA concentrations [30]. It is
unlikely that the higher AA concentrations destabilized membrane phospholipid, since
increasing DHA concentrations did not reduce initial velocity.
Inhibition of AA and DHA activation by Acsl4 to their respective acyl-CoA products by
VPA was characterized to be uncompetitive enzyme inhibition [30]. The Ki for VPA
inhibition of AA acylation by Acsl4 was 25 mM, somewhat less than the 36 mM for DHA
acylation. VPA did not inhibit palmitate acylation by Acsl4.
VPA’s inhibition of AA acylation by Acsl4 is consistent with VPA’s ability to reduce AA
turnover in brain phospholipids of unanesthetized rats [18]. However, although VPA
reduced DHA activation to DHA-CoA by recombinant Acsl4, it did not reduce DHA
turnover in rat brain phospholipid [16,34]. One explanation for this discrepancy is that
inhibition of acylation by Acsl4 at a given VPA concentration would have a 10-fold greater
effect on AA than DHA turnover, since the enzyme’s catalytic efficiency is 10-fold higher
AA than for DHA acylation. The net effect would be seen, within the limits of measurement
error, as a greater reduction of AA compared with DHA turnover in rat brain phospholipids.
The Ki for VPA inhibition of AA acylation by Acsl4 was 25 mM, compared with 14 mM by
a rat brain microsomal preparation [16]. However, a therapeutically relevant dose of VPA
(200 mg/kg, i.p.) in rats produces a brain VPA concentration of only 1.0 to 1.5 mM [17,35],
about 10-fold less than either in vitro Ki. This difference might be reconciled if VPA within
brain were at a concentration higher than the mean, consistent with evidence that it can be
accumulated in mitochondria, microsomes and other organelles[36–38]. Acsl4 is present in
these organelles [24,25]. The actual VPA concentration at the brain enzyme site (s) also may
depend on VPA’s access to Acsl4, which is localized on the inner membrane surface but,
unlike the other Acsl enzymes, is not integrated within the membrane bilayer [22,26].
Furthermore, Ki for purified Acsl4 can depend on conditions such as pH in the bath medium,
but the medium fatty acid or acyl-CoA binding proteins as in brain [39]. Differences
between brain Acsl4 and liver Acsl4 remain to be evaluated.
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It might be possible reconcile the difference between the Ki in vitro and the therapeutic brain
VPA concentration by identifying new compounds that inhibit AA acylation by recombinant
Acsl4, then testing whether these compounds also reduce AA turnover in rat brain
phospholipids in vivo [18]. Such compounds, if identified, then could be considered for
clinical trials in BD patients. A number of VPA analogs and like compounds, some of which
are not teratogenic, as is VPA, because they do not inhibit histone deacetylase [40–42],
could be considered in such a drug discovery paradigm.
The biologically effective concentration of an uncompetitive inhibitor may not be much less
than the concentration that gives an insurmountable blockade, whereas lower concentrations
may not produce much inhibition. Thus, uncompetitive inhibitors can have a relative narrow
therapeutic window before toxicity intervenes [43]. This appears to be the case for VPA,
whose therapeutic range in treating BD mania is between 45 to 100–125 μg/ml [44,45].
X-ray crystallography studies are unavailable for mammalian Acsl enzyme, but analysis of
the crystal structure from the distantly related acyl-CoA synthetase from Thermus
thermophilus HB8 suggests that a fatty acid-binding tunnel exists at the N-terminus [46].
Mutagenesis of Acsl4 suggests that amino acid residues at the hydrophobic end of the fatty
acid binding pocket in the enzyme determine its fatty acid preference and Km, whereas
changing an amino acid at the entry of the binding pocket can inactivate the enzyme [33].
Crystallizing and then studying the mammalian enzyme could help to characterize sites of
interaction with VPA and the basis of substrate inhibition by VPA.
Congenital changes in Acsl4 can lead to altered dendritic spine formation and contribute to
brain disease, and a deficiency of the ACSL4 gene is associated with X-linked mental
retardation [25,47]. The Alport syndrome with intellectual disability is a contiguous gene
deletion syndrome involving several genes on Xq22.3 including COL4A5 and ACSL4 [48].
In summary, Michaelis-Menten analysis indicates that recombinant rat liver Acsl4 activates
AA to AA-CoA by a mechanism inhibited at high substrate concentration, at a lower Km and
higher catalytic efficiency than for recombinant brain Acsl3, Acsl6v1 or Acsl6v2. Acsl4 also
activates DHA to DHA-CoA without substrate inhibition. VPA uncompetitively inhibits
conversion of AA to AA-CoA and of DHA to DHA-CoA by Acsl4, but not conversion of
AA to AA-CoA by Acsl3, Acsl6v1 or Acsl6v2. The 10-fold greater catalytic efficiency for
AA than DHA activation by Acsl4, when related to VPA’s reported ability to significantly
reduce AA but not DHA turnover in brain phospholipids of unanesthetized rats, suggests
that inhibition of Acsl4 is the basis for the reduced AA turnover. Differences in apparent
effective concentrations for the in vitro and in vivo effects might be reconciled
experimentally by comparing other inhibitors of Acsl4 under the two conditions.
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Recombinant rat Acsl3, Acsl4, Acsl6v1 and Acsl6v2-Flag proteins expressed in E. Coli
were analyzed by Western blotting with an anti-Flag M2 monoclonal antibody. Protein-
antibody complexes were visualized by chemiluminescence detection of horseradish
peroxidase linked to goat anti-mouse IgG. The molecular mass of the recombinant Acsl
isoenzymes was 74-kDa. The same E. Coli strain containing the identical plasmid without
the gene encoding for Acsl was used as control.
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Initial reaction velocity (V, nmol/min/mg protein) of (2a) Acsl3, (2b) Acsl6v1 and (2c)
Acsl6v2, plotted against increasing AA concentration [S] in the presence 0, 30, or 60 mM
VPA.
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(3a) Initial reaction velocity (V, nmol/min/mg protein) of Acsl4 plotted against increasing
AA concentration [S] in the presence of 0, 10, 30, 60 or 90 mM VPA, or of 30 mM LiCl [I].
(3b) Lineweaver-Burk plots for the reciprocal of enzyme activity (1/V) against the inverse of
substrate concentration, 1/[S] (1/[AA]).
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Initial reaction velocity V of Acsl4 plotted against increasing palmitic acid concentration [S]
in the presence of 0, 30, 60 or 90 mM VPA.
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(5a) Initial reaction velocity V of Acsl4 plotted against increasing DHA concentration [S] in
the presence of 0, 30, 60 or 90 mM VPA. (5b) Lineweaver-Burk plots of reciprocal of
enzyme activity (1/V) against 1/[S] (1/[DHA]).
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Initial reaction velocity V of Acsl4 plotted against increasing AA concentration [S] in
control solution, 60 mM sodium butyrate, or 60 mM sodium octanoate.
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Table 1
Kinetic constants for rat recombinant Acsl3, Acsl6v1 and Acsl6v2 with AA as substrate.
Isozyme Km (μM) Vmax (nmol/min/mg) Catalytic efficiency Vmax/(KmET) (min−1)
Acsl3 48 ± 5 8 ± 1 3 · 10−5
Acsl6v1 34 ± 2 2.9 ± 0.5 1.3 · 10−5
Acsl6v2 23 ± 3 0.52 ± 0.08 4 · 10−6
Data are means ± SD of triplicate assays. Km and Vmax with AA as substrate were calculated according to the Michaelis-Menten model (Eq. 1): V
= (VmaxS)/(Km+S), where Vmax is the maximal velocity, Km the Michaelis-Menten constant and S the substrate concentration, determined from
the data presented in Figure 2. GraphPad Prism 5 was used for best fit nonlinear regression analysis. ET is the total enzyme concentration per
reaction (mg/l).
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Table 2
Kinetic constants for recombinant rat Acsl4 and Ki values for VPA
Kinetic Parameters Substrate
AA DHA Palmitic Acid
Km (μM) 4.98 ± 1.41 26.63 ± 3.95 16.74 ± 6.25
Vmax (nmol/min/mg) 143.3 ± 11.1 121.4 ± 6.19 28.14 ± 3.64
Ki of VPA (mM) 24.93 ± 2.61 36.36 ± 5.22 NE
Ks of Substrate (μM) 0.86 ± 0.18 NE NE
Catalytic efficiency Vmax/(KmET) (min−1) 8.79 · 10−3 7.60 · 10−4 3.19 · 10−4
Data are means ± SD of triplicate assays. Km (Michaelis-Menten constant), Vmax (maximal initial reaction velocity) and Ks (dissociation rate
constant of the substrate) of AA as substrate, were calculated by fitting the data to Eq. 3, V = (VmaxS)/(Km+S(1+S/Ks), according to a substrate
inhibition model. Ki (dissociation rate constant of VPA as an uncompetitive inhibitor) was calculated by fitting the data to Eq. 4, V = (VmaxS)/
(Km+S(1+S/Ks+I/Ki)). For DHA and palmitic acid as substrates, the equation V = (VmaxS)/(Km+S) was used to determine Vmax and Km, while
Ki of VPA, with DHA as a substrate, was calculated by fitting the data to the equation: V = (VmaxS)/(Km+S(1+Io/Ki), a reduction of Eq. 3. ET is
the total enzyme concentration per reaction (mg/l). The corresponding enzyme parameters were determined from the data presented in Figures 3, 4
and 5 by using GraphPad Prism 5 for best fit nonlinear regression analysis. NE, no effect.
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